The aim of the present study was to examine the mechanisms responsible for the antinatriuretic effect of the selective, peripherally acting, nociceptin/orphanin FQ peptide (NOP) receptor partial agonist Ac-RYYRWKKKKKKK-NH 2 (ZP120). Using immunohistochemistry, we showed that in the cortex NOP receptors are expressed in the distal convoluted tubules, the connecting tubules, and the collecting ducts. Using clearance techniques, we evaluated renal excretory function during acute administration of ZP120 (1 nmol/kg/min) in chronically catheterized, conscious rats (n ϭ 8/group). To examine the hypothesis that ZP120 induces direct renal effects by modifying the activity of sodium transporters in the distal convoluted tubules or in the collecting ducts, ZP120-induced antinatriuresis was examined during coadministration of an inhibitor of the NaCl cotransporter, bendroflumethiazide, or a blocker of the epithelial sodium channel, amiloride, respectively. ZP120 produced a marked antinatriuresis [fractional excretion of sodium (FE Na ): ZP120, 0.3 Ϯ 0.1% versus control, 0.9 Ϯ 0.1%; p Ͻ 0.05] in sodium-replete rats. The natriuretic response to amiloride was significantly increased in ZP120-treated rats compared with controls (⌬FE Na : ZP120, 1.1 Ϯ 0.2% versus control, 0.5 Ϯ 0.2%; p Ͻ 0.01), whereas the effect of BFTZ was equal in ZP120-treated rats and controls. These results suggest that ZP120 exerts a direct renal NOP receptor-mediated stimulatory effect on the epithelial sodium channel in the collecting ducts.
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Nociceptin (N/OFQ), the endogenous ligand of the NOP receptor (Meunier et al., 1995; Reinscheid et al., 1995) , has been shown to have a variety of effects both in the central nervous system and peripherally. Central nervous system effects include induction of hyperalgesia in mice (Meunier et al., 1995) and modulation of feeding behavior and hormone secretion (for review, see Meunier, 1997) . Peripherally, nociceptin has been shown to induce vasodilation, bradycardia, increased urinary output, and antinatriuresis (for review, see Kapusta, 2000) .
Ac-RYYRWKKKKKKK-NH 2 (ZP120) is a peripherally acting partial NOP receptor agonist (Kapusta et al., 2005) that is composed of a pharmacologically active hexapeptide, Ac-RYYRWK-NH 2 , coupled to a chain of six lysine residues. The (Lys)6-moiety is also known as a structure-inducing probe, which through induction of ␣-helical structure impairs enzymatic access to the amide bonds in the backbone of the peptide and increases its enzymatic stability (Larsen, 1999) . Thus, relative to the unmodified hexapeptide, ZP120 displays increased potency in vitro and a longer duration of action in vivo (Rizzi et al., 2002; Kapusta et al., 2005) .
Acute infusion of nociceptin and ZP120 has been associated with increased urinary output and antinatriuresis. This pharmacological profile is interesting in regard to the acute treatment of water-retaining disease states, such as congestive heart failure. The mechanisms responsible for the aquaretic effect of ZP120 have been examined previously, but the tubular site of the antinatriuretic effect is at present unknown.
The aim of the present study was to examine the mechanisms responsible for the antinatriuretic effect of ZP120. Using immunohistochemistry, we show that NOP receptors are expressed in the distal convoluted tubules, the connect-ing tubules, and in the collecting ducts. Using clearance techniques, we evaluated renal hemodynamics and tubular function during acute administration of ZP120 in chronically instrumented, conscious animals. Based on our demonstration of NOP receptors in the distal convoluted tubules, the connecting tubules, and the collecting ducts, we hypothesized that ZP120 induces direct renal effects by acting on sodium transporters in the distal nephron downstream the thick ascending limb of Henle. To test this hypothesis, sodium handling in the distal convoluted tubules and the collecting ducts was evaluated by analysis of the natriuretic response to the sodium-chloride cotransporter (NCC) inhibitor bendroflumethiazide (BFTZ) or the epithelial sodium channel (ENaC) blocker amiloride during ZP120-induced antinatriuresis.
Materials and Methods
Experimental Animals. Male Wistar rats (250 g; Charles River, Sulzfeld, Germany) were used. The rats were housed at 22-24°C and 40 -70% humidity with a 12-h light/dark cycle (lights on from 8:00 AM to 8:00 PM). Before surgery, rats had free access to tap water and rodent diet (Altromin 1314; Altromin International, Lage, Germany) containing approximately 120 mmol/kg sodium, approximately 275 mmol/kg potassium, and 23% protein. All animal procedures followed the guidelines for the care and handling of laboratory animals established by the Danish government.
Immunohistochemistry. Untreated male Wistar rats were anesthetized with 4% (induction) and 2% (maintenance) isoflurane in N 2 O/O 2 (1:1). The abdominal cavity was opened, and the aorta was exposed. The left kidney was perfused in situ via the aorta with 0.1 M sodium cacodylate buffer, pH 7.4, containing 3% paraformaldehyde. A 19-gauge cannula was inserted into the aortic bifurcation, and kidney perfusion was facilitated by simultaneous puncture of the renal vein and compression of the aorta above the renal artery. Perfusion was performed at 260 mbar for 2 to 3 min.
Kidney sections were paraffin-embedded, and 2-m-thick slices were blocked in 1% bovine serum albumin, 0.2% gelatin, and 0.05% saponin in PBS; washed in 0.1% bovine serum albumin, 0.2% gelatin, 0.05% saponin in PBS; and incubated overnight at 4°C with a mouse monoclonal anti-calbindin antibody (D-28K, RDI-CALBINDINDabm; Fitzgerald Industries Int., Concord, MA) together with either a goat polyclonal anti-NOP receptor antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or a polyclonal rabbit anti-aquaporin 2 (AQP2) antibody (LL127; kindly provided by Søren Nielsen, University of Aarhus, Aarhus, Denmark). Sections were washed again and incubated with Alexa Fluor 546-conjugated goat anti-mouse (Invitrogen, Carlsbad, CA) and either Alexa Fluor 488 donkey anti-goat (Invitrogen) or fluorescein isothiocyanate-conjugated swine anti-rabbit (Dako Denmark A/S, Glostrup, Denmark) for 60 min at room temperature. Sections were examined using a TCS SP2 laser confocal microscope (Leica, Wetzlar, Germany) (Fenton et al., 2008) .
Clearance Experiments. Renal tubular function was evaluated in conscious, chronically catheterized rats. Permanent venous, arterial, and bladder catheters were implanted during anesthesia with 4% (induction) and 2% (maintenance) isoflurane in N 2 O/O 2 (1:1) . To keep catheters open for the following week, catheters were filled with a 50% glucose solution containing 10,000 IU/ml streptokinase (Streptase; Aventis Behring, Marburg, Germany) and 200 IU/ml heparin. After surgery, the rats were allowed to recover for 1 week. Buprenorphine (100 g/kg) was administered subcutaneously three times daily for 2 days for postoperative pain relief. From the time of surgery, animals were fed on a high sodium CNT, and CDs (arrows) . To identify the tubules with NOP receptor expression, rat cortical kidney sections were stained for AQP2 (CNT and CDs), the calcium transporter calbindin (DCT and CNT), and NOP receptor. Top, staining for AQP2 (green) and calbindin (red). Bottom, staining for NOP receptor (green) and calbindin (red). CCD, cortical collecting duct.
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org diet (Altromin 1311, supplemented with NaCl to contain 250 mmol sodium/kg; Altromin International) and offered free access to tap water and 0.9% NaCl drinking solution. Three days before the experiment, rats were switched to a high sodium diet (250 mmol sodium/kg) containing lithium citrate (12 mmol lithium/kg). The rats were accustomed to experimental restraining cages by 2 ϫ 2-h training on the days before the clearance experiment.
On the day of the experiment, rats were placed in restraining cages and 150 mM NaCl with tracer amounts of [ 3 H]inulin (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and [
14 C]tetraethylammonium bromide (TEA) (PerkinElmer, Alleroed, Denmark) was delivered intravenously at 1 ml/h throughout the clearance experiment. The arterial catheter was kept open by intra-arterial infusion of 150 mM NaCl containing 10 IU/ml heparin at 0.5 ml/h. After a 90-min equilibration period, infusion of ZP120 (1 nmol/kg/ min) in 150 mM NaCl at 0.5 ml/h was initiated. After another 90 min, either BFTZ (0.25 mg/h) (Sigma-Aldrich, Brøndby, Denmark) or amiloride hydrochloride (0.2 mg/kg/h) (Sigma-Aldrich) in saline at 0.5 ml/h was added, and infusions were continued for another 120 min. Then, 0.1% ethanolamine was added to bring BFTZ into solution. Throughout the ZP120 treatment period, urine volume losses were replaced by servo-controlled infusion of 50 mM glucose (Burgess et al., 1993; Jonassen et al., 1995) , whereas sodium losses were not replaced. The infusion protocol is illustrated in Fig. 1 .
Urine samples were collected every 30 min, and blood samples (300 l) were drawn from the arterial line at 0, 90, and 150 min and at the end of the experiment. Blood sample volumes were immediately replaced with heparinized donor blood (Jonassen et al., 1998 (Jonassen et al., , 2000 .
Clearances of [ 3 H]inulin, [ 14 C]TEA, lithium, and electrolytes were calculated for each urine collection period by the formula C ϭ U ϫ V/P, where U is urine concentration, P is plasma concentration, and V is urine flow. Inulin clearance was used as a marker for GFR , TEA clearance as a marker for effective renal plasma flow (Rasmussen et al., 1990) , and lithium clearance (C Li ) as a marker for the flow of tubular fluid from the proximal tubules (Thomsen, 1984) . Clearance of sodium/C Li and clearance of potassium/C Li were used as estimates of the fractional excretion (FE) of sodium and potassium, respectively, from the distal nephron. 
ZP120 Increases Sodium Reabsorption 535
at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
Downloaded from
Experimental Series. We conducted three experimental series. Series 1 examined effects of ZP120 alone and included group ZP120 (1 nmol/kg/min) (n ϭ 4); series 2 examined effects of BFTZ on ZP120-induced antinatriuresis and included groups ZP120 (1 nmol/kg/min) ϩ BFTZ (0.25 mg/h) (n ϭ 8) and vehicle ϩ BFTZ (0.25 mg/h) (n ϭ 8); and series 3 examined effects of amiloride on ZP120-induced antinatriuresis and included groups ZP120 (1 nmol/kg/min) ϩ amiloride (0.2 mg/kg/h) (n ϭ 9) and vehicle ϩ amiloride (0.2 mg/kg/h) (n ϭ 9).
Plasma Hormone Levels. In a different set of animals, the same diet and infusion protocol were used. Before and immediately after 90-min infusion of either ZP120 or vehicle, blood samples of 1 ml each were collected from the arterial catheter. These blood samples were used for determination of plasma concentrations of aldosterone and renin. Blood samples were immediately replaced by donor blood (Jonassen et al., 1998 (Jonassen et al., , 2000 .
Analytical Methods. Electrolytes in plasma and urine were measured by atomic absorption spectrometry, using a PerkinElmer series 2380 or a PerkinElmer Analyst 300 atomic absorption spectrometer. [
3 H]Inulin and [ 14 C]tetraethylammonium were determined by double-label scintillation counting on a PerkinElmer Tri-Carb 2800TR liquid scintillation counter. Urinary osmolality was determined by freeze point depression, using an Advanced model 2020 freezing depression osmometer (Advanced Instruments Inc., Norwood, MA). Plasma osmolality was measured using a Vapro vapor pressure osmometer (model 5520; Wescor Inc., Logan, UT). Plasma aldosterone levels were determined by a commercial kit (Coat-ACount Aldosterone; Diagnostic Products, Los Angeles, CA). Plasma renin concentration was determined using the "antibody-trapping technique" of Lykkegård and Poulsen (1976) , which is an ultramicroradioimmunoassay of generated angiotensin I. Plasma samples were diluted 20-to 80-fold with Tris buffer containing human albumin. Five microliters of these diluted samples was incubated with 20 ml of reaction mixture containing purified rat renin substrate (ϳ1200 ng of angiotensin I-equivalents/ml) for 24 h at 37°C. Incubation was followed by radioimmunoassay of generated angiotensin I. Plasma renin concentration was determined by comparison with renin standards obtained from the National Institute for Biological Standards and Control (Potters Bar, Herts, UK; 1 milli-Goldblatt unit ϭ 160 pg angiotensin I/ml/h).
Statistical Analyses. Overall differences for one-way classified data were analyzed using one-way analysis of variance for repeated measures followed by Tukey's test. Paired two-tailed t test was used to compare renal excretory responses in experimental group 1. Peak responses were defined as responses in the 30-min clearance period with maximal deflection relative to the last control period. All data are presented as mean Ϯ S.E.M. p values of Ͻ0.05 were considered statistically significant.
Results

Immunohistochemical Demonstration of NOP Receptors in the Distal Convoluted Tubules, Connecting
Tubules, and in the Cortical Collecting Ducts. To explore the expression pattern of the NOP receptor in kidney tubules, kidney sections from untreated rats were stained with antibodies against the Ca 2ϩ transporter calbindin, the water channel AQP2, and the NOP receptor. Calbindin is expressed in the distal convoluted tubules (DCT) and connecting tubules (CNT) (Bindels et al., 1991) , whereas AQP2 is localized to the collecting ducts (CDs) and connecting tubules (Nielsen et al., 1993; Kishore et al., 1996) . Double immunofluorescence staining revealed that the NOP receptor is expressed in the distal convoluted tubules, the connecting tubules, and in the collecting ducts (Fig. 2) . Calbindin and NOP receptors colocalized in distal convoluted tubules and in connecting tubules (Fig. 2, A and B) , and AQP2 and NOP receptors colocalized in collecting ducts (Fig. 2B) .
Antinatriuretic Effect of ZP120. In our previous studies on ZP120-induced renal excretory responses (Hadrup et al., 2004 (Hadrup et al., , 2007 , we failed to show a sustained antinatriuretic effect of ZP120. However, in these studies rats were in a sodium-deplete state with very low FE Na ; consequently, it was difficult to detect an antinatriuretic effect during these conditions. To ensure that rats used in the present clearance studies were sodium replete, we offered them a diet containing 250 mmol NaCl/kg, access to 150 mM NaCl drinking fluid, and we changed their light/dark cycle, so that lights were on from 8:00 AM to 8:00 PM. Furthermore, rats were infused with isotonic saline instead of a 50 mM glucose solution during the equilibration period. at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
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As shown in Fig. 3 , intravenous infusion of ZP120 (1 nmol/ kg/min) to conscious, chronically catheterized rats fed on a high sodium diet induced a marked increase in urine flow rate (V: ZP120, 76.2 Ϯ 7.3 versus control, 35.3 Ϯ 10.0 l/min/ 100 g BW; p Ͻ 0.05) along with antinatriuresis (FE Na : ZP120, 0.3 Ϯ 0.1% versus control, 0.9 Ϯ 0.1%; p Ͻ 0.05) (Fig. 3) . Mean arterial pressure (MAP), effective renal plasma flow (ERPF), GFR, and C Li were not affected by ZP120 infusion (data not shown).
Effects of BFTZ on ZP120-Induced Antinatriuresis. Our first hypothesis was that ZP120 might bind to the NOP receptor in the distal convoluted tubules and mediate stimulation of the NCC at this site. This would lead to increased reabsorption of sodium, which could explain the antinatriuretic response of ZP120. We therefore tested the natriuretic response of the specific NCC inhibitor BFTZ during ZP120-induced antinatriuresis.
ZP120 infusion alone increased urine flow significantly (V: ZP120, 68.6 Ϯ 11.4 versus control, 11.4 Ϯ 3.0 l/min/100 g BW; p Ͻ 0.001) and induced a borderline antinatriuretic response (FE Na : ZP120, 0.9 Ϯ 0.2 versus control, 1.5 Ϯ 0.2%; p ϭ 0.06). BFTZ increased FE Na in both groups. The level of significance was, however, smaller in ZP120-treated rats than in controls (FE Na : ZP120, from 0.9 Ϯ 0.2 to 2.8 Ϯ 0.4%; p Ͻ 0.05 and control, from 1.5 Ϯ 0.2 to 4.1 Ϯ 0.9%; p Ͻ 0.001) (Fig. 4 and 6) . Furthermore, BFTZ only increased UNaV significantly in the vehicle-treated rats (Table 1) . Likewise, FE K increased in both groups in response to BFTZ, but to a significantly greater level in the ZP120-treated rats compared with vehicle-treated rats (FE K : ZP120, from 15.9 Ϯ 2.3 to 44.4 Ϯ 3.8%; p Ͻ 0.001 and control, from 20.5 Ϯ 2.3 to 33.0 Ϯ 5.1%; p Ͻ 0.05) (Figs. 4 and 6) . Comparison of delta values for FE K revealed that the kaliuretic response to BFTZ was significantly greater in the ZP120-treated rats compared with vehicle-treated rats (Fig. 6) . There was no difference in MAP, ERPF, GFR, or C Li between the ZP120-treated rats and the controls (Table 2) .
These results suggest that the NCC sodium transporter is not activated by ZP120, because an activation of NCC by ZP120 would have led to a larger increase in FE Na in ZP120-treated rats than in control rats when administering the NCC inhibitor. Furthermore, the increased kaliuretic effect in response to BFTZ seen in the ZP120-treated rats (Table 1 ; Fig. 6 ) is compatible with ZP120-induced stimulation of ENaC-mediated sodium reabsorption in the collecting ducts.
Effects of Amiloride on ZP120-Induced Antinatriuresis. In accordance with our previous findings (Hadrup et al., 2004) , NOP receptors were identified in the cortical collecting ducts. To test the hypothesis that ZP120 exerts its antinatriuretic actions through stimulation of ENaC, the antinatriuretic effect of ZP120 was examined during coadministration of the ENaC blocker amiloride. Again, ZP120 produced a significant increase in diuresis (V: ZP120, 71.2 Ϯ 8.7 versus control, 12.4 Ϯ 1.4 l/min/100 g BW; p Ͻ 0.001) and a borderline antinatriuretic response compared with controls (FE Na : ZP120, 0.7 Ϯ 0.1% versus control, 1.4 Ϯ 0.2%; p Ͻ 0.06) (Fig. 5) . ZP120 did not significantly affect MAP, ERPF, GFR, or C Li (Table 3) . at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
As expected, coadministration of amiloride induced a small natriuretic effect in vehicle infused rats. However, following coadministration of amiloride to ZP120-infused rats, the natriuretic response was significantly increased (⌬FE Na : ZP120, 1.1% Ϯ 0.2 versus control, 0.5% Ϯ 0.2; p Ͻ 0.05) (Figs. 5 and 6 ). In both vehicle-and ZP120-infused rats, FE K was significantly decreased in response to amiloride coadministration (Figs. 5 and 6). The increased natriuretic effect of amiloride strongly suggests that ZP120 has a stimulatory effect on ENaC located in the collecting ducts.
Plasma Aldosterone and Plasma Renin Concentrations. The plasma aldosterone level and plasma renin concentration was determined in plasma collected just before and following 90 min i.v. ZP120 (1 nmol/kg/min) or vehicle infusion. Infusion of the NOP receptor ligand had no effect on the plasma level of aldosterone or plasma renin concentration compared with controls (Table 4) .
Discussion
In this study, we confirmed our previous findings demonstrating that the NOP receptor is expressed in the collecting ducts (Hadrup et al., 2004) . In addition, the NOP receptor was found in the distal convoluted tubules and in the connecting tubules. Intervention studies using a specific inhibitor of NCC (BFTZ) and a specific blocker of ENaC (amiloride) demonstrated that ZP120-induced antinatriuresis could be blocked by amiloride, whereas BFTZ induced less significant changes in ZP120-treated than in vehicle-treated rats. In further support of a direct effect of ZP120 on sodium handling in the collecting duct, this effect was independent of changes in plasma renin and plasma aldosterone levels.
Antinatriuresis during treatment with the NOP receptor agonist nociceptin was originally described by Kapusta et al. (1996) , and the same laboratory later confirmed NOP-receptor-mediated antinatriuresis using the selective partial NOP receptor agonist ZP120 (Kapusta et al., 2005) . In previous studies from our laboratory, we were unable to show a sustained antinatriuretic effect of ZP120 (Hadrup et al., 2004) when the compound was administered during conditions with low FE Na (ϳ0.1%, i.e., sodium-retaining conditions). In the present study, an amiloride-sensitive antinatriuretic effect of ZP120 was demonstrated in rats on a high sodium diet associated with a high FE Na (ϳ1%), suggesting that renal NOP receptor activation may stimulate sodium reabsorption in the collecting duct.
ZP120 was unable to decrease FEK per se in this study. This might explain why amiloride induced similar decreases in FEK in both vehicle-and ZP120-treated rats. The present study, therefore, does not answer questions of how ZP120 affects urinary potassium excretion.
The NOP receptor belongs to the G i family of G proteincoupled receptors and stimulation of the receptor inhibits adenylate cyclase activation, which could explain the effect on water reabsorption through inhibition of vasopressin type 2-receptor-mediated cAMP generation and thereby the regulation of AQP2 expression and membrane targeting (Nielsen et al., 1993; DiGiovanni et al., 1994) . However, in addition NOP receptors have been shown to activate MAP kinase and phospholipase C/[Ca 2ϩ ] (Hawes et al., 2000) . Whether one of these pathways is involved in the stimulatory effect on sodium reabsorption during NOP stimulation is at the present unknown.
In conclusion, NOP receptors are present in the cortical collecting ducts, in the distal convoluted tubules, and in the connecting tubules. We demonstrated that the selective, peripherally acting, partial NOP receptor agonist ZP120 exerts a stimulatory effect on distal sodium reabsorption through the amiloride-sensitive collecting duct sodium channel ENaC. In contrast, ZP120 has no effect on the BFTZ-sensitive sodium chloride cotransporter NCC, localized to the distal convoluted tubules. . Effect of BFTZ and amiloride in rats pretreated with ZP120 or vehicle. ‫,ء‬ p Ͻ 0.05 for ⌬FE Na in response to amiloride in ZP120-treated rats compared with response in control rats. †, p Ͻ 0.05 for ⌬FE K in response to BFTZ in ZP120-treated rats compared with response in control rats. 
